Aminoglycosides

Correct Answer

C — Gentamicin

Rationale

Gentamicin is an aminoglycoside — a class of antibiotics defined by their aminocyclitol ring linked to amino sugars and their activity against gram-negative bacteria. Vancomycin is a glycopeptide. Azithromycin is a macrolide. Doxycycline is a tetracycline. Recognizing gentamicin as the aminoglycoside among agents from other antibiotic classes is the entire task.

Correct Answer

D — Streptomycin

Rationale

Streptomycin is an aminoglycoside whose primary clinical role is in the treatment of tuberculosis and certain other specific infections including brucellosis, plague, and tularemia. Unlike tobramycin and amikacin, which are used for serious gram-negative infections, streptomycin is not a first-line agent for gram-negative bacteremia. Neomycin is restricted to topical and oral use and is never given systemically. Knowing streptomycin's categorical clinical role within the aminoglycoside class is the task here.

Correct Answer

A — Neomycin

Rationale

Neomycin is the aminoglycoside classified as restricted to topical formulations and oral bowel decontamination. Systemic parenteral administration is never used. Gentamicin, tobramycin, and amikacin are all given parenterally for serious gram-negative infections. Recognizing neomycin's categorical restriction within the aminoglycoside class is the task here.

Correct Answer

C — Amikacin

Rationale

Amikacin is classified as a semisynthetic aminoglycoside — it is derived from kanamycin by addition of a side chain at the 1-amino group. This distinguishes it from naturally produced aminoglycosides such as gentamicin, tobramycin, and streptomycin. Knowing amikacin's classification as a semisynthetic kanamycin derivative is the task here.

Correct Answer

B — A naturally produced aminoglycoside with particular utility against Pseudomonas aeruginosa, available in both parenteral and inhaled formulations

Rationale

Tobramycin is a naturally produced aminoglycoside with defining categorical features: particular potency against Pseudomonas aeruginosa and availability in both parenteral and inhaled formulations, making it the aminoglycoside of choice for Pseudomonas infections including pulmonary infections in cystic fibrosis. Option A describes amikacin. Option C describes streptomycin. Option D describes neomycin.

Correct Answer

A — Concentration-dependent killers

Rationale

Aminoglycosides are classified as concentration-dependent killers — the pharmacodynamic parameter that drives their efficacy is the ratio of peak drug concentration to the minimum inhibitory concentration (Cmax/MIC). Higher peak concentrations produce more rapid and complete bacterial killing regardless of how long the drug remains above the minimum inhibitory concentration. This contrasts with time-dependent killers such as beta-lactams, for which what matters is the duration of drug concentration above the minimum inhibitory concentration, not the peak. Aminoglycosides are bactericidal, not bacteriostatic, and have a prolonged post-antibiotic effect against gram-negative bacteria. These properties together support once-daily (extended-interval) dosing strategies.

Correct Answer

C — They bind the 30S ribosomal subunit, causing messenger ribonucleic acid misreading and production of aberrant proteins that disrupt the inner membrane, leading to irreversible bactericidal killing

Rationale

Aminoglycoside entry occurs in two stages. Initial low-level uptake (driven by the drug's polycationic charge interacting with the outer membrane) allows small quantities to reach the 30S ribosomal subunit. Ribosomal binding causes misreading of messenger ribonucleic acid codons, generating non-functional aberrant proteins. These proteins insert into the inner membrane, disrupting its integrity and allowing a larger second wave of aminoglycoside uptake — creating a self-amplifying killing cycle that produces rapid, irreversible bactericidal activity. Penicillin-binding protein binding is the mechanism of beta-lactams. 50S binding characterizes macrolides and chloramphenicol. Dihydrofolate reductase inhibition is the mechanism of trimethoprim.

Correct Answer

A — Aminoglycoside uptake into bacteria requires aerobic metabolism to energize the active transport process; anaerobes lack this energy source and cannot import the drug

Rationale

Aminoglycoside entry into bacterial cells is an energy-dependent process driven by the electrochemical gradient across the bacterial inner membrane. This gradient is maintained by aerobic electron transport chain activity. Obligate anaerobes cannot generate the requisite electrochemical gradient because they lack the aerobic metabolic machinery, so they are unable to concentrate aminoglycosides intracellularly regardless of whether the organism has a susceptible 30S ribosomal target. In vitro susceptibility tests may show activity because laboratory conditions may not fully replicate the anaerobic environment, but in vivo activity is negligible. This explains why aminoglycosides are never used as monotherapy for infections where anaerobic coverage is required.

Correct Answer

D — Aminoglycosides are concentration-dependent killers, so a single high peak dose produces greater bactericidal activity than the same total dose divided into smaller doses

Rationale

Aminoglycosides kill bacteria in a concentration-dependent manner — the higher the peak drug concentration relative to the minimum inhibitory concentration, the more rapid and complete the bactericidal effect. Concentrating the entire daily dose into a single administration generates a higher peak than dividing it, maximizing the Cmax/MIC ratio and bactericidal activity. This is the primary pharmacodynamic rationale for extended-interval dosing. Once-daily dosing does not maintain continuous drug concentrations above the minimum inhibitory concentration — there is typically a drug-free trough period — and the total daily drug exposure is similar to divided dosing. Extended-interval dosing also provides a drug-free trough that limits proximal tubular drug accumulation, but the primary rationale is pharmacodynamic, not toxicity reduction.

Correct Answer

B — Aminoglycosides accumulate in proximal tubular cells after glomerular filtration and cause tubular cell death at the site of drug concentration

Rationale

Aminoglycosides are freely filtered at the glomerulus and then taken up by proximal tubular epithelial cells in the renal cortex, where they accumulate to concentrations far exceeding plasma levels. This tubular accumulation causes lysosomal disruption and cell death — the primary mechanism of aminoglycoside nephrotoxicity. The resulting acute kidney injury is characteristically non-oliguric because distal nephron function remains intact, and serum creatinine elevation lags behind actual tubular injury because remaining nephrons compensate initially. Extended-interval dosing reduces this risk by providing a drug-free trough period during which tubular cells can clear accumulated drug before the next dose.

Correct Answer

A — Aminoglycosides irreversibly destroy cochlear sensory hair cells, which do not regenerate in mammals

Rationale

The cochlear sensory hair cells that transduce sound vibration into neural signals are the cellular target of aminoglycoside cochleotoxicity. Aminoglycosides accumulate in the endolymph of the inner ear and are taken up by hair cells, where they generate reactive oxygen species that cause cell death. Mammalian cochlear hair cells do not regenerate after injury — unlike hair cells in fish and birds, which can be replaced. Once destroyed, the cells are permanently absent and the resulting sensorineural hearing loss is irreversible. Initial injury typically affects outer hair cells in the basal turn of the cochlea, which process high-frequency sounds, explaining why high-frequency hearing loss is detected first on audiometry. Aminoglycoside cochleotoxicity is a sensorineural process involving hair cell destruction, not a conductive process affecting the tympanic membrane or ossicles.

Correct Answer

C — The combination carries substantially higher nephrotoxicity risk than either agent alone, with acute kidney injury rates reported at 20 to 35% or higher

Rationale

Combining vancomycin with an aminoglycoside produces synergistic nephrotoxicity that exceeds the risk of either drug used alone. Both agents independently accumulate in and injure renal tubular cells through related but distinct mechanisms. Together, the combination produces acute kidney injury in 20 to 35% or more of patients in observational studies — a rate substantially higher than with either agent alone. When this combination must be used, daily renal function monitoring, aggressive hydration, correction of electrolyte deficits, avoidance of additional nephrotoxins, and daily reassessment of whether the combination remains necessary are all required. Therapeutic drug monitoring reduces but does not eliminate the risk; target trough levels for both agents must be maintained strictly to minimize injury without sacrificing efficacy.

Correct Answer

D — Aminoglycoside-modifying enzymes chemically modify the drug by phosphorylation, acetylation, or adenylation, abolishing its affinity for the 30S ribosomal subunit

Rationale

Aminoglycoside-modifying enzymes are the dominant resistance mechanism in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. They chemically alter hydroxyl or amino groups on the aminoglycoside molecule through phosphorylation, acetylation, or adenylation. These chemical modifications alter the spatial configuration of the drug, preventing it from binding with adequate affinity to the 16S ribosomal ribonucleic acid of the 30S subunit. Without ribosomal binding, no messenger ribonucleic acid misreading occurs and the drug is rendered inactive. These enzymes are encoded on mobile genetic elements — plasmids, transposons, and integrons — allowing rapid horizontal transfer among diverse bacteria. Amikacin resists most of these enzymes because its molecular structure physically blocks the enzyme binding site. Ribosomal ribonucleic acid methylation (not modification of the drug itself) is a separate, distinct resistance mechanism causing high-level resistance to all aminoglycosides including amikacin.

Correct Answer

B — Amikacin has a bulkier molecular structure that sterically blocks the positions where aminoglycoside-modifying enzymes would otherwise modify the drug

Rationale

Amikacin is a semisynthetic aminoglycoside derived from kanamycin with an acyl side chain added at the 1-amino group. This bulky side chain physically blocks the hydroxyl and amino positions that aminoglycoside-modifying enzymes use as chemical modification sites on other aminoglycosides. With the enzyme attachment sites sterically protected, most phosphotransferases, acetyltransferases, and nucleotidyltransferases cannot modify amikacin, and the drug retains its ribosomal binding affinity even in organisms that enzymatically inactivate gentamicin and tobramycin. Amikacin still binds the same 16S ribosomal ribonucleic acid site as other aminoglycosides. The one resistance mechanism that defeats amikacin is ribosomal ribonucleic acid methyltransferase production, which modifies the ribosomal target rather than the drug itself — a mechanism that is increasingly co-located with carbapenemase genes on mobile plasmids.

Correct Answer

D — Ampicillin disrupts the enterococcal cell wall, allowing gentamicin to enter the organism and reach the 30S ribosomal subunit — a target it cannot access in sufficient quantities when used alone against enterococci

Rationale

Enterococci are intrinsically tolerant to the bactericidal activity of aminoglycosides and beta-lactams when used alone because the drug cannot accumulate in sufficient intracellular concentrations to kill. Aminoglycosides require an intact electrochemical gradient for energy-dependent uptake, and enterococcal cell wall structures limit this uptake. Ampicillin disrupts cell wall synthesis by inactivating penicillin-binding proteins, compromising membrane integrity and increasing inner membrane permeability. This allows gentamicin to enter the organism in quantities sufficient to bind the 30S ribosomal subunit, cause messenger ribonucleic acid misreading, and achieve bactericidal killing. The combination is synergistic — neither drug alone produces bactericidal activity against enterococci, but together they overcome the organism's intrinsic tolerance. Enterococci do not produce beta-lactamase as their primary resistance mechanism; the synergy mechanism is about drug uptake, not enzymatic protection.

Correct Answer

B — Gentamicin accumulated in proximal tubular epithelial cells and caused tubular cell necrosis; the preserved urine output and delayed creatinine rise are characteristic of aminoglycoside nephrotoxicity

Rationale

This presentation is the classic pattern of aminoglycoside nephrotoxicity. After glomerular filtration, gentamicin is taken up by proximal tubular epithelial cells in the renal cortex, where it accumulates to concentrations well above plasma levels, causing lysosomal disruption and tubular cell death. The resulting acute kidney injury is characteristically non-oliguric — urine output is preserved because distal nephron function is intact even as proximal tubular function fails. The onset after 5 to 10 days reflects the time needed for tubular drug accumulation to reach toxic levels. The 24 to 48 hour lag between tubular injury and serum creatinine rise occurs because surviving nephrons compensate before creatinine begins rising. Extended-interval dosing reduces this risk by providing daily drug-free trough periods that allow tubular cells to clear accumulated drug before the next dose.

Correct Answer

A — Inhaled tobramycin achieves high drug concentrations directly in the airways while producing minimal systemic absorption, avoiding the nephrotoxicity and ototoxicity associated with parenteral dosing

Rationale

The inhaled route of tobramycin exploits the anatomy of the target site. Patients with cystic fibrosis have chronic Pseudomonas aeruginosa colonization in the lower airways, and the goal of inhaled tobramycin is suppression — reducing bacterial burden and exacerbation frequency rather than eradication. By delivering tobramycin directly to the airway, the inhaled route achieves drug concentrations in bronchial secretions that far exceed minimum inhibitory concentrations for Pseudomonas aeruginosa. Because absorption across the respiratory epithelium is minimal, plasma concentrations remain far below those needed to cause nephrotoxicity or ototoxicity. This allows chronic long-term use — typically 28 days on, 28 days off — that would be impossible with parenteral dosing due to cumulative toxicity. Inhaled tobramycin reduces exacerbation frequency and improves lung function but does not eradicate Pseudomonas aeruginosa from the airway.

Correct Answer

C — Amikacin resists most aminoglycoside-modifying enzymes because its molecular structure sterically blocks the chemical modification sites used by those enzymes

Rationale

When gentamicin and tobramycin resistance is identified, the resistance mechanism is virtually always aminoglycoside-modifying enzyme production — phosphotransferases, acetyltransferases, or nucleotidyltransferases that chemically modify the drug at hydroxyl or amino groups, abolishing ribosomal binding affinity. Amikacin has a bulkier side chain at the 1-amino group that physically blocks the positions where most of these enzymes attach, preventing chemical modification and preserving amikacin's affinity for the 30S ribosomal subunit. All aminoglycosides, including amikacin, bind the 16S ribosomal ribonucleic acid of the 30S subunit — there is no alternative ribosomal target. When amikacin susceptibility testing is needed but not yet available, empiric use is reasonable after gentamicin and tobramycin resistance is confirmed, with the exception of organisms producing ribosomal ribonucleic acid methyltransferases, which confer high-level resistance to amikacin as well and require genotypic testing to detect.